Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2021;160:744–54.
Google Scholar
Balachandran VP, Beatty GL, Dougan SK. Broadening the Impact of Immunotherapy to pancreatic cancer: Challenges and opportunities. Gastroenterology. 2019;156:2056–72.
Google Scholar
Bear AS, Vonderheide RH, O’Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38:788–802.
Google Scholar
Gromisch C, Qadan M, Machado MA, Liu K, Colson Y, Grinstaff MW. Pancreatic adenocarcinoma: Unconventional approaches for an unconventional disease. Cancer Res. 2020;80:3179–92.
Google Scholar
Schizas D, Charalampakis N, Kole C, Economopoulou P, Koustas E, Gkotsis E, et al. Immunotherapy for pancreatic cancer: A 2020 update. Cancer Treat Rev. 2020;86:102016.
Google Scholar
Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, et al. Microenvironmental determinants of pancreatic cancer. Physiol Rev. 2020;100:1707–51.
Google Scholar
Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527–40.
Google Scholar
Leinwand J, Miller G. Regulation and modulation of antitumor immunity in pancreatic cancer. Nat Immunol. 2020;21:1152–59.
Google Scholar
Ammirante M, Rosati A, Arra C, Basile A, Falco A, Festa M, et al. IKK{gamma} protein is a target of BAG3 regulatory activity in human tumor growth. Proc Natl Acad Sci USA. 2010;16:7497–502.
Ray K. Pancreatic cancer: New insights into PDAC growth promotion via a BAG3-mediated paracrine loop. Nat Rev Gastroenterol Hepatol. 2015;12:669.
Google Scholar
Rosati A, Basile A, D’Auria R, d’Avenia M, De Marco M, Falco A, et al. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nat. Commun. 2015;6:8695.
Google Scholar
Iorio V, Rosati A, D’Auria R, De Marco M, Marzullo L, Basile A, et al. Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8+ T cell number and tumour growth in pancreatic cancer. Gut. 2018;67:780–2.
Google Scholar
Iorio V, De Marco M, Basile A, Eletto D, Capunzo M, Remondelli P, et al. CAF-derived IL6 and GM-CSF cooperate to induce M2-like TAMs-letter. Clin Cancer Res. 2019;25:892–3.
Google Scholar
Li C, An MX, Jiang JY, Yao HB, Li S, Yan J, et al. BAG3 suppresses loading of Ago2 to IL6 mRNA in pancreatic ductal adenocarcinoma. Front Oncol. 2019;9:225.
Google Scholar
De Marco M, Turco MC, Marzullo L. BAG3 in tumor resistance to therapy. Trends Cancer. 2020;6:985–8.
Google Scholar
McCracken MN, Cha AC, Weissman IL. Molecular pathways: Activating T cells after cancer cell phagocytosis from blockade of CD47 “don’t eat me” signals. Clin Cancer Res. 2015;21:3597–601.
Google Scholar
Liu Q, Wen W, Tang L, Qin C-J, Qin CJ, Lin Y, et al. Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity. Oncoimmunology. 2016;5:e1183850.
Google Scholar
Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276:145–64.
Google Scholar
Yanagita T, Murata Y, Tanaka D, Motegi SI, Arai E, Daniwijaya EW, et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017;2:e89140.
Google Scholar
Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, et al. Selective SIRPα blockade reverses tumor T-cell exclusion and overcomes cancer immunotherapy resistance. J Clin Invest. 2020;130:6109–23.
Google Scholar
Kuo TC, Chen A, Harrabi O, Sockolosky JT, Zhang A, Sangalang E, et al. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. J Hematol Oncol. 2020;13:160.
Google Scholar
Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPα immune checkpoint. Immunity. 2020;52:742–52.
Google Scholar
Liu J, Xavy S, Mihardja S, Chen S, Sompalli K, Feng D, et al. Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy. JCI Insight. 2020;5:e134728.
Google Scholar
Zhang W, Huang Q, Xiao W, Zhao Y, Pi J, Xu H, et al. Advances in anti-tumor treatments targeting the CD47/SIRPα axis. Front Immunol. 2020;11:18.
Google Scholar
Behl C. Breaking BAG: The co-chaperone BAG3 in health and disease. Trends Pharm Sci. 2016;37:672–88.
Google Scholar
Verjan Garcia N, Umemoto E, Saito Y, Yamasaki M, Hata E, Matozaki T, et al. SIRPα/CD172a regulates eosinophil homeostasis. J Immunol. 2011;187:2268–77.
Google Scholar
Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160:324–38.
Google Scholar
Beatson R, Sproviero D, Maher J, Wilkie S, Taylor-Papadimitriou J, Burchell JM. Transforming growth factor-β1 is constitutively secreted by Chinese hamster ovary cells and is functional in human cells. Biotechnol Bioeng. 2011;108:2759–64.
Google Scholar
Basile A, De Marco M, Festa M, Falco A, Iorio V, Guerriero L, et al. Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer. Mol Oncol. 2019;13:1388–99.
Google Scholar
Storz P, Crawford HC. Carcinogenesis of pancreatic ductal adenocarcinoma. Gastroenterology. 2020;158:2072–81.
Google Scholar
Bulle A, Lim KH. Beyond just a tight fortress: Contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct Target Ther. 2020;5:249.
Google Scholar
Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochim Biophys Acta Rev Cancer. 2021;1875:188461.
Google Scholar
Peran I, Dakshanamurthy S, McCoy MD, Mavropoulos A, Allo B, Sebastian A, et al. Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice. Gastroenterology. 2021;160:1359–72.e13.
Google Scholar
Crawford HC, Pasca di Magliano M, Banerjee S. Signaling networks that control cellular plasticity in pancreatic tumorigenesis, progression, and metastasis. Gastroenterology 2019;156:2073–84.
Google Scholar
Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579–96.
Google Scholar
Belle JI, DeNardo DG. A single-cell window into pancreas cancer fibroblast heterogeneity. Cancer Discov. 2019;9:1001–2.
Google Scholar
Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-induced JAK/ STAT signaling is antagonized by TGFbeta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9:282–301.
Google Scholar
Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9:1102–23.
Google Scholar
Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, et al. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat Commun. 2019;10:3637.
Google Scholar
Garcia PE, Adoumie M, Kim EC, Zhang Y, Scales MK, El-Tawil YS, et al. Differential contribution of pancreatic fibroblast subsets to the pancreatic cancer stroma. Cell Mol Gastroenterol Hepatol. 2020;10:581–99.
Google Scholar
Helms E, Onate MK, Sherman MH. Fibroblast heterogeneity in the pancreatic tumor microenvironment. Cancer Discov. 2020;10:648–56.
Google Scholar
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174–86.
Google Scholar
Steele NG, Biffi G, Kemp SB, Zhang Y, Drouillard D, Syu L, et al. Inhibition of hedgehog signaling alters fibroblast composition in pancreatic cancer. Clin Cancer Res. 2021;27:2023–37.
Google Scholar
Feldmann K, Maurer C, Peschke K, Teller S, Schuck K, Steiger K, et al. Mesenchymal plasticity regulated by Prrx1 drives aggressive pancreatic cancer biology. Gastroenterology 2021;160:346–61.e24.
Google Scholar
Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: A strained relationship. Biochim Biophys Acta Rev Cancer. 2020;1873:188356.
Google Scholar
Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017;551:340–45.
Google Scholar
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–48.
Google Scholar
Boulter L, Bullock E, Mabruk Z, Brunton VG. The fibrotic and immune microenvironments as targetable drivers of metastasis. Br J Cancer. 2021;124:27–36.
Google Scholar
Böttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4:784–92.
Google Scholar
Williford JM, Ishihara J, Ishihara A, Mansurov A, Hosseinchi P, Marchell TM, et al. Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv. 2019;5:eaay1357.
Google Scholar
Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature. 2020;584:624–29.
Google Scholar
Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12:eaav7431.
Google Scholar
